| Autor: |
Annane D; Department of Intensive Care, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Garches, France; School of Medicine Simone Veil, University of Versailles Saint Quentin, University Paris-Saclay, Versaillles, France; Fédération Hospitalo-Universitaire SEPSIS, University Paris-Saclay, INSERM, Garches, France., Pittock SJ; Department of Neurology, Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA., Dunn D; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Kulasekararaj A; Department of Haematological Medicine, King's College Hospital, National Institute of Health Research, Wellcome King's Clinical Research Facility, King's College London, London SE5 9RS, UK. Electronic address: austin.kulasekararaj@nhs.net. |
| Jazyk: |
angličtina |
| Zdroj: |
The Lancet. Respiratory medicine [Lancet Respir Med] 2023 Sep; Vol. 11 (9), pp. e81. Date of Electronic Publication: 2023 Jun 09. |
| DOI: |
10.1016/S2213-2600(23)00186-8 |
| Abstrakt: |
Competing Interests: DA has received funding, paid to institution, from Alexion, AstraZeneca Rare Disease and is co-inventor on a patent pending (WO2021211940A1). SJP has received funding, paid to institution, from grants; contracts; consulting fees; and honoraria and travel expenses for lectures, advisory boards, and conference attendance from Alexion, AstraZeneca Rare Disease. He receives royalties from a patent (9,891,219B2). DD is an employee of Alexion, AstraZeneca Rare Disease, owns stock in AstraZeneca, and is a co-inventor on a patent pending (WO2021211940A1). AK has received funding, paid to institution, from Alexion, AstraZeneca Rare Disease; consulting fees from Regeneron, Samsung, Silence Therapeutics, and Novo Nordisk; and honoraria and support for attending meetings and travel from Alexion, AstraZeneca Rare Disease, Amgen, Sobi, Celgene, Bristol Myers Squibb, Biocryst, Pfizer, Roche, Novartis, and Janssen. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
